Trial Profile
A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs YYB 101 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Status changed to completed according to result presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results (n=22) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.